SINGAPORE (Jan 7): Dealmaking in the global healthcare sector is forecast to rise modestly this year after 2019 “started with a bang” with news of US pharmaceutical giant Bristol-Myers Squibb’s intended acquisition of Celgene for US$74 billion ($100.5 billion).

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply